NL-OMON49723已完成2 期
A Randomized, Double Blind, Placebo Controlled, Phase 2a Study to Assess the Clinical Efficacy of ISIS 721744, a Second Generation Ligand Conjugated Antisense Inhibitor of Prekallikrein, in Patients with Hereditary Angioedema - ISIS 721744-CS2
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Documented diagnosis of HAE-1/HAE-2 (for inclusion in Part A) or HAE-nC1-INH
- •(for inclusion in Part B);
- •- Participants must experience a minimum of 2 HAE attacks (assessed by the
- •Angioedema Activity Score [AAS] and confirmed by the investigator) during the
- •screening period;
- •- Access to, and the ability to use, 1 or more acute medication(s) to treat
- •angioedema attacks.
排除标准
- •- Anticipated use of short-term prophylaxis for angioedema attacks for a
- •pre-planned procedure during the Screening or Study Periods.
- •- Concurrent diagnosis of any other type of recurrent angioedema, including
- •acquired or idiopathic angioedema.
- •- History of acquired coagulopathies or bleeding diathesis.
- •- Active infection with human immunodeficiency virus (HIV), hepatitis C or
- •chronic hepatitis B.
- •- Malignancy within 5 years, except for basal or squamous cell carcinoma of the
- •skin or carcinoma in situ of the cervix that has been successfully treated.
- •- Treatment with another investigational drug or biological agent within 1
- •month or 5 half-lives, whichever is longer, of Screening.
- •- Exposure to any of the following medications:
- •a. Angiotensin-converting enzyme (ACE) inhibitors or any estrogen containing
- •medications with systemic absorption (such as oral contraceptive or hormonal
- •replacement therapy) within 4 weeks prior to Screening.
- •b. Chronic prophylaxis with Lanadelumab within 10 weeks prior to Screening.
- •c. Oligonucleotides (including small interfering RNA) within 4 months of
- •Screening if single dose received, or within 12 months of Screening if multiple
- •doses received.
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Double Blind, Placebo Controlled, Phase II Study Evaluating the Efficacy and Safety of RP101 in Combination with Gemcitabine Administered as First-Line Treatment to Subjects with Unresectable, Locally Advanced, or Metastatic Pancreatic AdenocarcinomaEUCTR2007-004102-27-NLSciClone Pharmaceuticals, Inc.153
进行中（未招募）
1 期
This is a randomized, double-blind, Placebo controlled trial to evaluate the efficacy of ISIS 721744 in Patients with Hereditary AngioedemaMedDRA version: 20.0Level: PTClassification code 10019860Term: Hereditary angioedemaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersHereditary AngioedemaEUCTR2019-001044-22-GBIonis Pharmaceuticals, Inc.24
进行中（未招募）
不适用
A Randomized, Double Blind, Placebo Controlled, Phase II Study Evaluating the Efficacy and Safety of RP101 in Combination with Gemcitabine Administered as First-Line Treatment to Subjects with Unresectable, Locally Advanced, or Metastatic Pancreatic AdenocarcinomaEUCTR2007-004102-27-HUSciClone Pharmaceuticals, Inc.153
进行中（未招募）
不适用
A Randomized, Double Blind, Placebo Controlled, Phase II Study Evaluating the Efficacy and Safety of RP101 in Combination with Gemcitabine Administered as First-Line Treatment to Subjects with Unresectable, Locally Advanced, or Metastatic Pancreatic Adenocarcinomametastatic pancreatic cancerMedDRA version: 9.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticMedDRA version: 9.1Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableEUCTR2007-004102-27-DESciClone Pharmaceuticals, Inc.153
已完成
2 期
A clinical trial to study the effects of LNP1892 (A Lupin Novel Product) in chronic kidney disease patients with secondary hyperparathyroidism (SHPT) condition who are taking dialysis treatment & not taking dialysis treatment.CTRI/2017/07/009179upin Limited189